BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Monday, May 11, 2026
Home » Topics » Financings

Financings
Financings RSS Feed RSS

Clarity’s sarcophagine technology

Clarity raises AU$203M to advance copper-based radiopharma pipeline

July 29, 2025
By Tamra Sami
No Comments
Radiopharma Clarity Pharmaceuticals Ltd. raised AU$203 million (US$132.22 million) in an institutional placement on Australia’s Securities Exchange to advance its late-stage pipeline of copper-based radiopharmaceuticals.
Read More

Financings for July 28, 2025

July 28, 2025
Med-tech firms raising money in public or private financings, including: Aidoc.
Read More

Financings for July 28, 2025

July 28, 2025
Biopharmas raising money in public or private financings, including: Abivax, Absci, Algernon, Everest, Hemostemix, Omeros, Pharvaris, Targepeutics.
Read More

China financings pick up: Everest’s $200M placement, Leads’ $189M IPO

July 28, 2025
By Tamra Sami
No Comments
Chinese financings are picking up, with Everest Medicines Ltd. raising US$200 million and Nanjing-based Leads Bioloabs Co. Ltd. listing on the main board of the Hong Kong Stock Exchange in a $189 million IPO.
Read More

Financings for July 25, 2025

July 25, 2025
Med-tech firms raising money in public or private financings, including: Intelligent Bio, Olympus, Revival Healthcare, Swan.
Read More

Financings for July 25, 2025

July 25, 2025
Biopharmas raising money in public or private financings, including: Abivax, Alzecure, Astra, Palisade, TCG Labs Soleil, Tharimmune, Windtree.
Read More
Chris Nave, co-founder and managing partner, Brandon Capital Partners

Brandon Capital closes sixth life sciences fund at AU$439M

July 25, 2025
By Tamra Sami
No Comments
Brandon Capital Partners Pty Ltd., Australia’s largest life sciences venture capital firm, announced the final close of its sixth fund at AU$439 million (US$288 million), the VC’s largest fund to date.
Read More

Financings for July 24, 2025

July 24, 2025
Med-tech firms raising money in public or private financings, including: Mentice, Ispecimen, Scopio Labs.
Read More
HKEX exterior

34 mainland China biotechs file for Hong Kong IPO in H1 2025

July 24, 2025
By Marian (YoonJee) Chu
No Comments
Thirty-six biotechnology, pharmaceutical and medical device companies sought a capital raise on the Hong Kong Stock Exchange in the first half (H1) of 2025, a review by BioWorld found. Of those, 34 companies were from mainland China.
Read More
HKEX exterior

34 mainland China biotechs file for Hong Kong IPO in H1 2025

July 24, 2025
By Marian (YoonJee) Chu
No Comments
Thirty-six biotechnology, pharmaceutical and medical device companies sought a capital raise on the Hong Kong Stock Exchange in the first half (H1) of 2025, a review by BioWorld found. Of those, 34 companies were from mainland China.
Read More
Previous 1 2 … 70 71 72 73 74 75 76 77 78 … 671 672 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for May 8, 2026.
  • Rendering of a key measles protein targeted by neutralizing human antibodies

    First measles treatment advances as vaccination rates drop

    BioWorld
    Scientists at the La Jolla Institute for Immunology have identified and characterized human antibodies that neutralize the measles virus by blocking its entry...
  • Infensa Bioscience identifies new ASIC blockers

    BioWorld Science
    Infensa Bioscience Pty Ltd. has patented new acid-sensing ion channel 1 (ASIC) blockers potentially useful for the treatment of stroke, among others.
  • Close up of bow of cruise ship

    Hantavirus is ‘sentinel’ more than acute pandemic threat

    BioWorld
    News of eight infections and three deaths so far due to an emerging zoonotic virus has brought back unhappy memories of the early days of SARS-CoV-2. At a press...
  • Neurology illustration

    Italy’s Angelini pays $4.1B cash for rare disease specialist Catalyst

    BioWorld
    Italian family-owned Angelini Pharma SpA is making its first move into the U.S. market, acquiring rare diseases specialist Catalyst Pharma Inc. in an all-cash...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing